基于DNA甲基化区分甲状腺良恶性病变
研究比较甲状腺癌与良性病变的基因组DNA甲基化谱,筛选出6个差异甲基化CpG位点并构建分类器,在手术标本和细针穿刺标本中验证,良恶性鉴别敏感性94.3%、特异性82.4%,不明确细胞学病例中敏感性100%、特异性89%。
要点
- 6个CpG甲基化分类器可辅助鉴别甲状腺良恶性病变。
- 手术标本验证敏感性90.7%、特异性75.4%。
- 不明确细胞学FNAB中敏感性100%、特异性89%。
核心结论
- 基于DNA甲基化的诊断工具可用于甲状腺结节术前筛查,有望避免不必要的甲状腺切除术。
研究设计与样本
- 比较60例乳头状癌、10例滤泡状癌与50例非肿瘤组织和17例良性病变的全基因组甲基化谱。
- 在161例甲状腺肿瘤和69例良性病变术后标本及55例前瞻性FNAB中验证6个CpG位点。
主要发现
- 乳头状癌和滤泡状癌分别发现2130和19个差异甲基化CpG。
- 6个CpG模型鉴别良恶性病变敏感性94.3%、特异性82.4%。
- 外部数据验证敏感性91.3-97.4%、特异性87.5%。
- 手术标本验证敏感性90.7%、特异性75.4%(5/6个CpG)。
- FNAB验证恶性确诊者敏感性86.7%、特异性89.5%;细胞学不明确者敏感性100%、特异性89%。
临床怎么用
- 可用于FNAB细胞学不明确结节的辅助诊断,减少不必要手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The differential diagnosis of thyroid nodules using fine-needle aspiration biopsy (FNAB) is challenging due to the inherent limitation of the cytology tests. The use of molecular markers has potential to complement the FNAB-based diagnosis and avoid unnecessary surgeries. In this study, we aimed to identify DNA methylation biomarkers and to develop a diagnostic tool useful for thyroid lesions. Methods: Genome-wide DNA methylation profiles (Illumina 450K) of papillary thyroid carcinoma (PTC = 60) and follicular thyroid carcinoma (FTC = 10) were compared with non-neoplastic thyroid tissue samples (NT = 50) and benign thyroid lesions (BTL = 17). The results were confirmed in publicly available databases from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) using the same DNA methylation platform. Two classifiers were trained to discriminate FTC and PTC from BTL. To increase the applicability of the method, six differentially methylated CpGs were selected and evaluated in 161 thyroid tumors and 69 BTL postsurgical specimens and 55 prospectively collected FNAB using bisulfite-pyrosequencing. Results: DNA methylation analysis revealed 2130 and 19 differentially methylated CpGs in PTC and FTC, respectively. The CpGs confirmed by GEO and TCGA databases showing high areas under the receiver operating characteristic curve in all sample sets were used to train our diagnostic classifier. The model based on six CpGs was able to differentiate benign from malignant thyroid lesions with 94.3% sensitivity and 82.4% specificity. A similar performance was found applying the algorithm to TCGA and GEO external data sets (91.3-97.4% sensitivity and 87.5% specificity). We successfully evaluated the classifiers using a bisulfite-pyrosequencing technique, achieving 90.7% sensitivity and 75.4% specificity in surgical specimens (five of six CpGs). The study comprising FNAB cytology materials corroborated the applicability and performance of the methodology, demonstrating 86.7% sensitivity and 89.5% specificity in confirmed malignant tumors, and 100% sensitivity and 89% specificity in cases with indeterminate cytology. Conclusions: A novel diagnostic tool with potential application in preoperative screening of thyroid nodules is reported here. The proposed protocol has the potential to avoid unnecessary thyroidectomies.
引用
- Barros-Filho MC, Dos Reis MB, Beltrami CM, et al. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions. Thyroid. 2019. PMID: 31328658. doi:10.1089/thy.2018.0458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。